Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF-SBRT Plus Toripalimab and Chemotherapy in Stage II-III NSCLC
NCT07608159Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2026
- Primary completion
- May 2029
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 2-year event-free survival rate. Planned start May 2026; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07608159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608159.